Clinical studies indicated an enhanced antileukemic effect of allogeneic bone marrow transplantation (BMT), as compared with autologous BMT. After allogeneic HLA-identical BMT, donor-derived cytotoxic T lymphocytes (CTLs) directed at minor histocompatibility (mH) antigens on the recipients, tissues can be shown. To evaluate the antileukemic reactivity of mH antigen-specific CTLs, we analyzed the expression of mH antigens on circulating lymphocytic and myeloid leukemic cells. We show that the defined mH specificities HA-l through HA-5 and H-Y are present on leukemic cells, indicating that rnH antigen-specific CTLs ONE MARROW transplantation (BMT) using allogeneic HLA-identical donors as a treatment modality for hematologic malignancies is complicated by the occurrence of graft-versus-host disease (GVHD). Despite the deleterious effects of GVHD, clinical studies indicate an associated decreased leukemia relapse rate, commonly designated as the graft-versus-leukemia (GVL) effect."4
tion of clonogenic myeloid leukemic ~el1s.l~ Recognition of mH antigens on leukemic cells by mH antigen-specific CTLs may explain the GVL effect of allogeneic HLA-identical BMT. To study the recognition of mH antigens on circulating leukemic cells of lymphocytic and myeloid origin, the CTL clones specific for HA-1 to HA-5 and the male mH antigen H-Y were used.
We describe here the recognition of these mH antigens on circulating lymphocytic and myeloid leukemic cells by mH antigen-specific CTLs and hypothesize the participation of these CTLs in the GVL effect of allogeneic BMT.
MATERIALS AND METHODS
Patients and preparulion of leukemic samples. Leukemic samples (n = 24) were selected from patients expressing HLA-AI and/ or HLA-A2, which are the HLA class I restriction molecules for mH-specific CTL clones (ie, HLA-A I for HA-3, and HLA-A2 for HA-1, -2, -4, and -5 and H-Y). Six patients with acute myeloid leukemia, 3 patients with chronic myeloid leukemia, 7 patients with acute lymphocytic leukemia, and 8 patients with chronic lymphocytic leukemia (including B-prolymphocytic leukemia and hairy cell leukemia) were tested. Leukemic samples from peripheral blood were obtained after informed consent at diagnosis before therapy. The cells were centrifuged over Ficoll-Isopaque (density, 1.077 g/mL) and the leukocytes in the interface were subsequently stored in liquid nitrogen. In case of patients with a hairy cell leukemia, spleens were used as a source of leukemic cells. Parts of these spleens were minced, and leukocytes were obtained after Ficoll-Isopaque density centrifugation and subsequently stored in liquid nitrogen. The number of leukemic cells in all samples was more than 90% as measured by morphology, immunophenotyping, and/or cytogenetic analysis (data not shown).
mH antigen-specific C T L clones. Cytotoxic T-cell lines HA-l through HA-5 and H-Y were obtained from 5 patients after allogeneic BMT as previously de~cribed.~,' These T-cell lines were cloned by limitingdilution, as described in detail? The CD8+, T-cell receptor a/@+ CTL clones were expanded in culture medium, consisting ofRPMI 1640 (GIBCO, Grand Island, NJ) supplemented with 15% selected human serum, 20 Cetus units (CU) recombinant interleukin-2 (rIL-2)/mL (EuroCetus, Amsterdam, The Netherlands), 3 mmol/L glutamin, 50 &mL gentamycin, and 1 pg/mL leukoagglutinin A (Pharmacia, Uppsala, Sweden). A feedermixture containing irradiated allogeneic peripheral blood mononuclear cells and patient's irradiated pretransplant Epstein-Barr virustransformed B-cell line was added. The mH antigen specificity was shown by differential recognition of lymphocytes from various HLA-identical sibling pairs and population studies? The clones were stored in liquid nitrogen.
To study the recognition of mH antigens on circulating leukemic cells, these mH antigen-specific CTL clones were used. CTL clones with anti-HLA-A 1 or anti-HLA-A2 specificity were used as controls for the presence of the HLA-class I restriction molecules in the cell-mediated lysis (CML) assays. The day before the CML assay was performed, the clones were thawed and cultured in RPMI 1640 (GIBCO), supplemented with 50 pg/mL gentamycin, 15% selected human serum, and 20 CU rIL-Z/mL (Eurocetus).
Preparation of target cells. Thawed leukemic cells were used in all experiments. The leukemic cells were preincubated overnight in RPMI 1640 (GIBCO), supplemented with 10% selected human serum, 3 mmol/L L-glutamin, and 50 pg/mL gentamycin. To obtain normal lymphocytes, leukemic cell suspensions were cultured in culture medium as described above, supplemented with 0. I pg/ mL phytohemagglutinin (Wellcome, Dartford, UK). After 3 days, the cells were washed and expanded in culture medium in the presence of 20 CU rIL-Z/mL (EuroCetus) for at least 3 days. The suspensions used contained 290% CD3+ IL2-stimulated normal lymphocytes (data not shown).
CML. CML assays were performed using a standard %r-release assay. Briefly, target cells were incubated with 100 pCi Na:lCrO4 (Dupont NEN Products, Boston, MA) for I hour at 37'C and washed. Then, 5 X IO' viable target cells were incubated with CTL clones at different effector to target (E/T) ratios for 4 hours at 37°C. After incubation, the supernatant was collected and radioactivity was measured in a gamma counter. striction molecule HLA-A2, but lacking the mH antigen as determined on corresponding IL-2-stimulated normal lymphocytes in a "Cr-release assay using the mH antigen-specific clones described above, were used as controls for steric hindrance.
To determine the influence of expression of adhesion molecules on CML of IL-2-stimulated normal lymphocytes, blocking studies were performed. Target cells were incubated with radioactive chromium as described above, and 5 X IO3 viable target cells per well were subsequently incubated with saturating amounts of monoclonal antibodies against CD 1 la or CD1 8 (LFA-I complex; Central Laboratory for the Blood-transfusion Service CLB, Amsterdam) for 30 minutes at 37°C. As a control, target cells with no antibodies added were run in parallel. Afterwards, the target cells were incubated for 4 hours at 37'C with the HA-2 mH antigen-specific CTL clone at an E/T ratio of 5: 1. Thereafter, the supernatant was collected and radioactivity was measured using the procedure previously described.
Immunofluorescence. To estimate the number of HLA-A2 molecules on leukemic cells and IL-2-stimulated normal lymphocytes, viable cells were incubated with saturating amounts of CRl l-351 (an anti-HLA-A2/A28 monoclonal antibody; courtesy of Dr S. 
RESULTS
Expression of mH antigens. We compared lysis of leukemic cells and IL-2-stimulated normal lymphocytes derived from the same individual by mH antigen-specific CTL clones and CTL clones recognizing the HLA restriction molecules HLA-A1 and HLA-A2. Results are given in Fig  1A (lymphocytic leukemias) and Fig 1 B (myeloid leukemias) . All mH antigens present on IL-2-stimulated normal lymphocytes could also be detected on the corresponding leukemic cells. These results also show that mH antigen-specific CTLs can lyse lymphocytic and myeloid leukemic cells. IL-2-stimulated normal lymphocytes or leukemic cells from HLA-A 1 -positive patients were lysed only by the HA-3 mH antigen-specific CTL clone (HLA-A I restricted), and IL-2-stimulated normal lymphocytes and leukemic cells from patients typing HLA-A2 were recognized only by the HA-l, HA-2, HA-4, HA-5, and H-Y mH antigen-specific CTLs (results not shown).
Compared with IL-2-stimulated normal lymphocytes, leukemic cells of lymphocytic origin appeared to be less susceptible to lysis by the HA-2 mH antigen-specific CTL clone and the HLA-A2 CTL clone. This is shown in Table I , in which lysis by the HA-l, HA-2, HA-3, and HLA-A2 CTL clones at different effector to target ratios is given.
Cold target inhibition. Cold target inhibition experiments with the HA-2 mH antigen-specific CTL clone and the anti-HLA-A2 CTL clone were performed to analyze the observed differences in susceptibility to CML between IL-2-stimulated normal lymphocytes and lymphocytic leukemic cells. For this purpose, the HA-2 mH antigen-specific CTL clone was further expanded. Results from representative experiments are given in Fig 2. Cold IL-2-stimulated normal lymphocytes inhibit lysis of radiolabeled IL-2-stimulated normal lymphocytes by the HA-2 mH antigen-specific CTL clone and the anti-HLA-A2 CTL clone in a dose-dependent manner (Fig 2A and B) . The decreased sensitivity to lysis by the HA-2 mH antigen-specific CTL clone and the HLA-A2 CTL clone of lymphocytic leukemic cells as compared with that of the corresponding IL-2-stimulated normal lymphocytes is confirmed by these studies. However, cold leukemic cells are less effective in inhibiting lysis of radiolabeled IL-2-stimulated lymphocytes by the CTL clones used. These studies confirm the decreased sensitivity to lysis by the HA-2 mH antigen-specific CTL clone and the anti-HLA-A2 CTL clone of lymphocytic leukemic cells as compared with that of the corresponding IL-2-stimulated normal lymphocytes. The observation that IL-2-stimulated normal lymphocytes are more susceptible to target cell lysis than the corresponding leukemic cells is further shown in the titration curves in Fig 2C and D. Immunofluorescence. To explain the decreased susceptibility of lymphocytic leukemic cells to lysis by the HA-2 mH antigen-specific CTL clone and the anti-HLA-A2 CTL clone, we analyzed the expression of the HLA restriction molecule and cellular adhesion molecules. First, the number of HLA-A2 molecules on IL-2-stimulated normal lymphocytes and the corresponding leukemic cells from 9 patients with lymphocytic leukemias was quantified by immunofluorescence using a flow cytometer. Results (in ar- Results, obtained using an HLA-A2-specific monoclonal antibody and a flow cytometer (as described in Materials and Methods), are in arbitrary units.
~~~~
Abbreviations: T-ALL, T-acute lymphoblastic leukernla; 8-ALL, Bacute lymphoblastic leukemia; PLL, prolymphocytic leukemia; HCL, hairy cell leukemia (both negative) and CD49D (expressed in uniform quantities on all cells tested).
Blocking studies. To determine the importance of impaired expression of CD1 la/CDI 8 on susceptibility to CML, blocking studies were performed. IL-2-stimulated normal lymphocytes from 2 patients were used as targets for the HA-2 mH antigen-specific CTL clone with and without the addition of monoclonal antibodies against CD1 la or CD18. The results are given in Table 4 . Blocking of CD1 la but in particular of CD 18 inhibits lysis by this particular CTL clone, emphasizing the importance of these adhesion molecules.
DISCUSSION
After BMT, donor-derived mH antigen-specific CTL activity directed against the recipient can be shown in particular but not exclusively in patients with chronic GVHD. A Table 3 Control  5  8  6  6  3  8  CD1 l a  66  14  96  38  83  90  CD18  42  9  56  14  35  30  VLA-1  7  8  6  8  8  6  CD498  5  7  6  9  4  6  CD49D  26  19  31  20  29  18  CD54  7  10  12  15  6  27 Results are given in arbitrary fluorescence units. Control refers to the Abbreviations: NL, normal lymphocytes; Leuk, leukemic cells.
use of the GAM/FITC conjugate alone. Effector is the HA-2 mH antigen-specific CTL clone at an E/T ratio of 5: 1. Control denotes lysis without the addition of monoclonal antibodies to CD1 l a or CD1 8. Values represent the percentage of specific lysis.
number of mH antigens have been characterized. CTL clones specific for the male mH antigen H-Y and the nonsexlinked mH antigens HA-I , HA-2, HA-3, HA-4, and HA-5, which are recognized in a classical HLA class I-restricted fashion, have been
Using the latter clones, we show in this study that circulating leukemic cells of lymphocytic and myeloid origin express the defined mH antigens that are present on the patient's IL-%-stimulated normal lymphocytes. Therefore, mH antigen-specific CTL clones are capable of exerting potent HLA-restricted antigen-specific lysis of circulating leukemic cells. Recently, we have also shown that mH antigen-specific CTLs can inhibit growth of myeloid clonogenic precursor cells in an antigendependent HLA class I-restricted f a s h i~n . '~ Herewith, our data further support the notion that the antirecipient reactivity after allogeneic BMT includes also leukemic myeloid precursor cells and circulating leukemic cells, and thus may provide an explanation for the GVL effect of allogeneic transplantation.
Compared with IL-2-stimulated normal lymphocytes, leukemic cells of lymphocytic origin are less susceptible to CML by the HA-2 mH antigen-specific CTL clone, as is shown in Table 1 and Fig 1. However, it should be noted that IL-2-stimulated normal lymphocytes are T lymphocytes, whereas most leukemic lymphocytes are either of B-or T-cell origin. This decreased susceptibility is most pronounced when HA-2 mH antigenspecific lysis of IL-2-stimulated normal lymphocytes and lymphocytic leukemic cells is compared, a phenomenon that did not occur for myeloid leukemic cells.
To analyze this decreased susceptibility to lysis, cold target inhibition experiments were performed. The results from these studies confirm that IL-2-stimulated normal lymphocytes are preferentially lysed by these two clones as compared with IL-2-stimulated normal lymphocytes, because cold lymphocytic leukemic cells in increasing cold/ hot ratios hardly inhibit lysis of hot IL-2-stimulated normal lymphocytes (Fig 2) . Again, this decreased susceptibility does not exclusively apply for the HA-2 mH antigen-specific CTL clone, because comparable results were obtained with the anti-HLA-A2 CTL clone recognizing the HLA class I restriction molecule (Table l) .
Absence of the HLA restriction molecule leads to escape from lysis by mH antigen-specific CTLs and CTLs recognizing the HLA restriction element.I4 We therefore enumerated the number of HLA-A2 molecules on the cell surface of IL-2-stimulated normal lymphocytes and lymphocytic leukemic cells from 9 patients. The results show that in all cases the HLA-A2 molecule was present (Table 2) and that there are no differences between IL-2-stimulated normal lymphocytes and lymphocytic leukemic cells in the expression of HLA-A2.
Thus, impaired expression of this restriction molecule appears not to be the mechanism responsible for decreased lysis of lymphocytic leukemic cells as compared with corresponding IL-2-stimulated normal lymphocytes. This is in concordance with the observation that there are no differences in susceptibility to lysis by the HA-l and HA-3 mH antigen-specific CTL clones between IL-2-stimulated normal lymphocytes and leukemic cells, indicating that impaired expression of the HLA restriction element is unlikely.
We recently showed that hairy cell leukemias lack expression of CD I la, and that induction of CD 1 la/CD l8 (LFA-I ) and CD54 (ICAM-1) enhances susceptibility to T-cellmediated cytot~xicity.'~ Therefore, we quantified the number of CD1 l a/CD l8 and CD54 adhesion molecules on IL-2-stimulated normal lymphocytes, lymphocytic leukemic cells, and a myeloid leukemic cell. The expression of CD1 Ia/CD18 is impaired on the lymphocytic leukemic cells of both patients tested as compared with IL-2-stimulated normal lymphocytes. This may contribute to the decreased susceptibility of lymphocytic leukemic cells to lysis by this particular mH antigen-specific CTL clone and the anti-HLA-A2 CTL clone, as compared with IL-2-stimulated normal lymphocytes and myeloid leukemias.
To determine the influence of impaired expression of adhesion molecules on CML, we investigated whether blocking of CD 1 la or CD 18 on IL-2-stimulated normal lymphocytes would lead to decreased susceptibility to lysis by the HA-2 mH antigen-specific CTL clone (Table 4) .
These results again underscore the importance of cellular adhesion molecules in the process of T-cell-mediated cytoAlternatively, the decreased susceptibility of lymphocytic leukemic cells to CML by the HA-2 mH antigen-specific CTL clone and the HLA-A2-specific CTL clone could be caused by the physiology of the clones themselves as well as by the post-BMT donors from whom these clones were derived.
In conclusion, we have shown that circulating leukemic cells of both lymphocytic and myeloid leukemic origin are susceptible to antigen-specific HLA class I-restricted lysis by mH antigen-specific CTL clones, indicating that mH antigen-specific CTLs may play a role in the antileukemic effect of allogeneic BMT. Leukemic cells of lymphocytic origin are less susceptible to T-cell-mediated cytotoxicity by particular CTL clones as compared with IL-2-stimulated normal lymphocytes. This decreased susceptibility is not the result of impaired expression of the HLA class I molecule but may be explained by impaired expression of the LFA-1 adhesion molecule, although it cannot be ruled out that this phenomenon is caused by unique properties of the clones used.
Antirecipient mH antigen-specific reactivity can be shown in patients with and without clinical GVHD, as we have recently shown.* Therefore, the presence of mH antigen-specific CTLs in vivo need not imply the existence of GVHD. This is in concordance with our recent observation that mH antigens are differentially expressed on keratinocytes," indicating that mH antigen-specific CTLs need not necessarily damage keratinocytes because the latter may lack the mH antigen recognized by these CTLs. Therefore, it is conceivable that antirecipient mH antigen-specific CTLs exert antileukemic reactivity without affecting GVHD target organs. Thus, donor-derived mH antigen-specific CTLs recognizing the recipients' leukemic cells but not normal host cells (in contrast to the clones we presently used) could possibly be applied as adjuvant immunotherapeutic agents in the treatment of leukemia.
